# Study to Explore the Mechanism of Action of Ocrelizumab and B-Cell Biology in Participants With Relapsing Multiple Sclerosis (RMS) or Primary Progressive Multiple Sclerosis (PPMS)

> **NCT02688985** · PHASE3 · COMPLETED · sponsor: **Genentech, Inc.** · enrollment: 131 (actual)

## Conditions studied

- Relapsing Multiple Sclerorsis
- Multiple Sclerosis, Primary Progressive

## Interventions

- **DRUG:** Ocrelizumab
- **PROCEDURE:** Lumbar Puncture
- **DRUG:** Methyloprednisolone
- **DRUG:** Antihistamine

## Key facts

- **NCT ID:** NCT02688985
- **Lead sponsor:** Genentech, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-04-29
- **Primary completion:** 2023-04-11
- **Final completion:** 2023-04-11
- **Target enrollment:** 131 (ACTUAL)
- **Last updated:** 2024-06-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02688985

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02688985, "Study to Explore the Mechanism of Action of Ocrelizumab and B-Cell Biology in Participants With Relapsing Multiple Sclerosis (RMS) or Primary Progressive Multiple Sclerosis (PPMS)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02688985. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*